Xiamen Lp Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2012-11-02
- Employees
- 101
- Market Cap
- -
- Website
- http://www.lppharma.com
Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC
Phase 3
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Drug: IV Palonosetron 0.25 mg
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Xiamen LP Pharmaceutical Co., Ltd
- Target Recruit Count
- 328
- Registration Number
- NCT05199818
- Locations
- 🇺🇸
Orchard Healthcare research, Inc., Skokie, Illinois, United States
🇺🇸Pacific Cancer Medical Center, Anaheim, California, United States
🇺🇸Tri-County Hematology & Oncology Associates, Massillon, Ohio, United States
Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting
Phase 2
Completed
- Conditions
- Nausea With Vomiting Chemotherapy-Induced
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Xiamen LP Pharmaceutical Co., Ltd
- Target Recruit Count
- 22
- Registration Number
- NCT04592198
- Locations
- 🇺🇸
Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸Ocala Oncology Center PL DBA Florida Cancer Affiliates, Ocala, Florida, United States
🇺🇸Edward H. Kaplan MD & Associates, Skokie, Illinois, United States
© Copyright 2025. All Rights Reserved by MedPath